Vaxcyte
Vaxcyte Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation conjugate vaccines designed to prevent bacterial infectious diseases, prominently featuring its lead vaccine candidate VAX-24 for the prevention of invasive pneumococcal disease. The company utilizes advanced protein engineering, synthetic chemistry, and carrier protein technologies to develop vaccines providing broader protection against complex bacterial strains. Its core business operations encompass biopharmaceutical research, vaccine formulation engineering, clinical trial execution, and pharmaceutical product development. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and strategic research collaborations. Vaxcyte holds a pioneering market position in advanced bacterial vaccine engineering. The company is headquartered in San Carlos, California, United States, and its common stock trades on the Nasdaq Global Select Market.
9 of the funds FundTelligence covers report a position in Vaxcyte.
- Legal name
- Vaxcyte Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 9
Funds holding Vaxcyte
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 3.16 % (largest positions only, September 2026)
- DNB Bioteknologi — DNB · 1.65 % (full portfolio disclosed, September 2026)
- JPM US Small Cap Growth Fund — JPM · 0.92 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.75 % (full portfolio disclosed, September 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.66 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.61 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.09 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.06 % (partially disclosed portfolio, June 2026)
Showing the 8 largest of 9 funds holding it.